BrightPath Biotherapeutics Co (TSE:4594) Other Current Payables: 円120.35 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4594 BrightPath Biotherapeutics Co Ltd TSE:4594
44 GF Score
Price 円48.00
GF Value 円4.61
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is BrightPath Biotherapeutics Co Other Current Payables?

BrightPath Biotherapeutics Co TSE:4594 +2.13% 44 Other Current Payables is 円120.35 Mil as of Mar. 2026. GuruFocus rates TSE:4594 with a GF Score™ of 44/100 and a GF Value™ of 円4.61 (Significantly Overvalued). The stock has 4 warning signs investors should review.

BrightPath Biotherapeutics Co's Other Current Payables for the quarter that ended in Mar. 2026 was 円120.35 Mil.

BrightPath Biotherapeutics Co's quarterly Other Current Payables declined from Mar. 2025 (円82.68 Mil) to Sep. 2025 (円0.00 Mil) but then increased from Sep. 2025 (円0.00 Mil) to Mar. 2026 (円120.35 Mil).

BrightPath Biotherapeutics Co's annual Other Current Payables increased from Mar. 2024 (円52.73 Mil) to Mar. 2025 (円82.68 Mil) and increased from Mar. 2025 (円82.68 Mil) to Mar. 2026 (円120.35 Mil).

BrightPath Biotherapeutics Co Other Current Payables Related Terms

BrightPath Biotherapeutics Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for BrightPath Biotherapeutics Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrightPath Biotherapeutics Co Other Current Payables Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.65 56.72 52.73 82.68 120.35

BrightPath Biotherapeutics Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.73 0.00 82.68 0.00 120.35
TSE:4594
44GF Score
BrightPath Biotherapeutics Co Ltd TSE:4594
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BrightPath Biotherapeutics Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of 円120.35 Mil mean?
BrightPath Biotherapeutics Co (TSE:4594) has a Other Current Payables of 円120.35 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on BrightPath Biotherapeutics Co and its competitors.
Is BrightPath Biotherapeutics Co's Other Current Payables too high?
BrightPath Biotherapeutics Co's current Other Current Payables is 円120.35 Mil. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Other Current Payables compare to VRTX and REGN?
BrightPath Biotherapeutics Co's Other Current Payables of 円120.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on BrightPath Biotherapeutics Co and its competitors. BrightPath Biotherapeutics Co's current Other Current Payables is 円120.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co (TSE:4594) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.61, compared to a current price of 円48.00 — trading 941.2% above its estimated fair value. The current Other Current Payables is 円120.35 Mil. BrightPath Biotherapeutics Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Other Current Payables is 円120.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?

Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued. The current stock price of 円48.00 is trading 941.2% above its estimated GF Value™ of 円4.61. GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.

Key valuation signals for TSE:4594:

  • Other Current Payables: 円120.35 Mil
  • GF Value™: 円4.61 vs. price of 円48.00 (941.2% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BrightPath Biotherapeutics Co Business Description

Address 2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
44GF Score

Get the complete analysis for TSE:4594

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円48.00
Price
円4.61
GF Value